


Autumn 2025

## ADCs & beyond



**Preview**

Autumn 2025

**SPECIAL**

**Publication date:**  
**23 October, 2025**

# ADCs & beyond

## Get on board!

### Hot topics in antibody drug conjugates & radiopharmaceuticals

Antibody-drug conjugates and targeted radiopharmaceuticals promised chemotherapies and radiotherapies with fewer side effects by delivering cytotoxic cargos more specifically to the site of action, usually in tumours. However, despite approved drugs, there is still a great need for optimisation in terms of tumour selectivity, linker stability, stoichiometric drug-to-antibody ratio, payload or even the generation and expression of tumour-specific antibody-like targeting molecules. This special feature presents the latest developments in a market that is opening up major growth opportunities for service providers in particular. Become visible in EUROPEAN BIOTECHNOLOGY'S ADCs & beyond special feature and present your offer/portfolio to customers.

### Present your expertise

ADC and radiopharmaceutical developers, radioisotope providers, AI and analytics specialists, CDMROs, and antibody engineers will have the opportunity to present their latest products, services, and equipment in this special, which will find extra circulation through our official partner, SLAS, in the USA. European Biotechnology Magazine goes out to decision makers throughout the entire European life sciences sector and in the USA. Take advantage of to the journal's highly relevant readership and grab this opportunity to target your audience!

### Topics to be covered

Services & equipment: AI/wet lab-guided antibody optimisation and selection, anti-aggregation of multispecific antibodies, combination with T/NK cell engagers, novel payloads and linker technologies, shielding of payloads, novel manufacturing approaches, process development & upscaling, process monitoring, TME-selective release strategies, affinity modulation, ADC/radiopharma in vivo monitoring, safety switches

---

#### **Editorial Deadline** **08-10-2025**

Editorial contact:  
**Thomas Gabrielczyk**  
Tel.: +49-30-264921-50  
Fax: +49-30-264921-11  
t.gabrielczyk@biocom.de

#### **Booking Deadline** **10-10-2025**

Marketing contact:  
**Oliver Schnell**  
Tel.: +49-30-264921-45  
Fax: +49-30-264921-11  
o.schnell@biocom.de

#### **Publication Date** **23-10-2025**

Marketing contact:  
**Andreas Macht**  
Tel.: +49-30-264921-54  
Fax: +49-30-264921-11  
a.macht@biocom.de

# Special: ADCs & beyond Meet your audience!

## European Biotechnology

is published in co-operation with  
the following organisations:



**European Biotechnology NETWORK**  
european-biotechnology.net



**yebn**  
Young European Biotech Network  
yebn.eu



**LISA LIFE SCIENCE AUSTRIA**  
lifescienceaustria.at



**BIOTECH AUSTRIA**  
biotechaustria.org



**slas**  
Come Transform Research  
slas.org



**medicines for europe**  
medicinesforeurope.com



**ibec**  
For Irish Business  
ibec.ie/ibia



**DANSKBIOTEK**  
danskbiotek.dk



**Holland BIO**  
hollandbio.nl



**GASB**  
gasb.de



**P-BIO**  
www.p-bio.org



**BioPartner**  
biopartner.co.uk



**france biotech**  
france-biotech.org



**FEDERCHIMICA ASSOBIOTEC**  
assobiotec.federchimica.it



**sweden BIO**  
swedenbio.com



**HUNGARIAN BIOTECHNOLOGY**  
hungarianbiotech.org



**CEBR**  
cebr.net



**ASE BIO**  
asebio.com



**Bioteknologirådet**  
bioteknologiradet.no



**FINNISH BIOINDUSTRIES**  
suomenbioteollisuus.fi



**BIO.BE**  
bio.be



**Swiss Biotech Association**  
swissbiotech.org

EUROPEAN BIOTECHNOLOGY covers the biotechnology sector of the current 27 EU member states, Norway, Switzerland, and UK. If you would like to subscribe, please refer to [european-biotechnology.com](http://european-biotechnology.com)